Ironsides Asset Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

Ironsides Asset Advisors, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 01, 2023	SELL	$85.07 - $94.48 $34,028 - $37,792	-400 Reduced 14.62%	2,336 $206,000
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $17,336 - $20,060	-200 Reduced 6.81%	2,736 $237,000
Q3 2022 Nov 04, 2022	BUY	$82.16 - $96.94 $2,464 - $2,908	30 Added 1.03%	2,936 $249,000
Q2 2022 Aug 09, 2022	SELL	$71.48 - $86.85 $2,144 - $2,605	-30 Reduced 1.02%	2,906 $241,000
Q4 2021 Feb 04, 2022	SELL	$71.72 - $91.47 $99,690 - $127,143	-1,390 Reduced 32.13%	2,936 $259,000
Q3 2021 Nov 16, 2021	SELL	$74.77 - $85.47 $149,540 - $170,940	-2,000 Reduced 31.62%	4,326 $334,000
Q2 2021 Aug 06, 2021	SELL	$75.51 - $84.79 $78,530 - $88,181	-1,040 Reduced 14.12%	6,326 $528,000
Q1 2021 May 07, 2021	BUY	$74.73 - $90.69 $1,494 - $1,813	20 Added 0.27%	7,366 $556,000
Q4 2020 Feb 10, 2021	BUY	$72.61 - $90.2 $11,617 - $14,432	160 Added 2.23%	7,346 $644,000
Q3 2020 Nov 10, 2020	SELL	$71.87 - $131.03 $213,382 - $389,028	-2,969 Reduced 29.24%	7,186 $547,000
Q1 2020 May 11, 2020	BUY	$71.37 - $96.85 $440,709 - $598,048	6,175 Added 155.15%	10,155 $858,000
Q4 2019 Jan 21, 2020	SELL	$64.27 - $86.37 $704,077 - $946,183	-10,955 Reduced 73.35%	3,980 $337,000
Q2 2019 Aug 01, 2019	BUY	$80.35 - $93.9 $314,570 - $367,618	3,915 Added 35.53%	14,935 $1.28 Million
Q4 2018 Feb 13, 2019	BUY	$80.14 - $106.07 $603,053 - $798,176	7,525 Added 215.31%	11,020 $938,000
Q1 2018 May 04, 2018	SELL	$77.67 - $92.63 $15,534 - $18,526	-200 Reduced 5.41%	3,495 $283,000
Q3 2017 Nov 07, 2017	BUY	$80.6 - $94.95 $297,817 - $350,840	3,695	3,695 $344,000

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Ironsides Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ironsides Asset Advisors, LLC with notifications on news.